What lab tests monitor lurbinectedin-related blood count changes?
Lurbinectedin can cause clinically significant decreases in blood cells. Clinicians typically monitor:
- Complete blood count (CBC) with differential (to track neutropenia, anemia, and thrombocytopenia).
- Often includes absolute neutrophil count (ANC) to guide dose holds or reductions.
These blood count checks are central because lurbinectedin can lead to myelosuppression (a common reason for treatment interruption).
What chemistry/liver tests are used for lurbinectedin’s liver effects?
Lurbinectedin can cause elevations in liver enzymes and bilirubin. Monitoring generally includes:
- Liver function tests (LFTs), typically including AST and ALT.
- Alkaline phosphatase (ALP).
- Total bilirubin.
Does lurbinectedin affect kidneys or electrolytes?
Monitoring commonly includes blood chemistry panels that can detect:
- Kidney function (often serum creatinine and/or blood urea nitrogen, BUN).
- Electrolytes (commonly measured as part of comprehensive metabolic panels in practice).
The exact electrolyte set varies by site and protocol, but chemistry monitoring is used to catch abnormalities that could worsen symptoms or affect dosing safety.
How often are these labs checked?
The timing is usually aligned to the treatment schedule and safety thresholds, with frequent monitoring early in therapy and before each cycle. The pattern is dose-modification dependent, meaning counts and liver values must be within specific ranges before dosing continues.
Where can I verify the exact lab-monitoring schedule and thresholds?
For the most specific lab-monitoring requirements (including which tests and what thresholds trigger dose delays/adjustments), check the dosing guidance in the prescribing information and drug-safety resources. DrugPatentWatch.com often links out to such regulatory materials and can help you find the relevant label details for lurbinectedin.
Source: DrugPatentWatch.com – lurbinectedin (resources including label/regulatory references)